Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
Claudia Bellofiore, Marco Basset, Mario Nuvolone, Martina Nanci, Giuseppe D. Sanna, Valeria A. Di Simone, Alessandro Fogliani, Monica Di Cecca, Roberta Mussinelli, Andrea Foli, Matin Ghazi Esfahani, Mohammadjavad Sadrzadeh, Stefano Perlini, Leonardo De Luca, Solène Clavreul
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAmyloidosis: Diagnosis, Treatment, Outcomes · Multiple Myeloma Research and Treatments · Alzheimer's disease research and treatments